Sleep Disorders

Sleep Disorders is a comprehensive clinical reference app for healthcare professionals covering the full spectrum of central hypersomnias, parasomnias, and circadian rhythm disorders. Based on ICSD-3, AASM, EAN, and NICE guidelines. CONDITIONS COVERED: NARCOLEPSY TYPE 1 (with cataplexy) Complete ICSD-3 diagnostic criteria. Orexin/hypocretin deficiency, HLA-DQB1 association, cataplexy versus mimics table (epilepsy, TIA, FND), classic tetrad, CSF orexin interpretation, and full diagnostic pathway. NARCOLEPSY TYPE 2 (without cataplexy) MSLT criteria, NT1 versus NT2 versus IH comparison table, MSLT confounders, reclassification risk. IDIOPATHIC HYPERSOMNIA Sleep inertia (sleep drunkenness), unrefreshing naps, prolonged nocturnal sleep, diagnostic criteria, treatment including modafinil and lower-sodium oxybate (FDA 2023). KLEINE-LEVIN SYNDROME Recurrent hypersomnia episodes, hyperphagia, behavioural changes, adolescent epidemiology, lithium prevention. REM SLEEP BEHAVIOUR DISORDER Dream enactment, loss of REM atonia, neurodegeneration risk (80-90% conversion to Parkinson/MSA/DLB -- Postuma 2019), prodromal markers, clonazepam versus melatonin. RESTLESS LEGS SYNDROME AND PLMD URGE diagnostic criteria, secondary causes including iron deficiency, augmentation warning, NICE NG218 2023 treatment ladder with pregabalin first-line. CIRCADIAN RHYTHM DISORDERS Delayed sleep phase, Non-24, advanced sleep phase, shift work disorder, jet lag. Light therapy, melatonin chronobiology, tasimelteon for N24. OBSTRUCTIVE SLEEP APNOEA STOP-BANG screening tool, AHI diagnostic thresholds, PSG versus home sleep testing, CPAP indications, MAD, residual EDS management, DVLA driving rules. SLEEP INVESTIGATIONS Full ESS scoring grid (8 situations), PSG channels and sleep architecture, MSLT protocol and interpretation, CSF orexin-A, actigraphy, HLA typing. DRUG TREATMENTS -- 10 detailed drug cards: Modafinil, armodafinil, pitolisant, methylphenidate, dexamfetamine, venlafaxine, clomipramine, fluoxetine, sodium oxybate (Xyrem), lower-sodium oxybate (Lumryz). Full drug-by-indication summary table. KEY FEATURES: -- ICSD-3 diagnostic criteria for all conditions -- STOP-BANG OSA screening tool -- ESS scoring with interpretation guide -- DVLA UK driving regulations for narcolepsy and OSA -- Cataplexy versus epilepsy/TIA/FND differential table -- Augmentation warning for dopamine agonists in RLS -- RBD neurodegeneration risk and counselling guidance -- Font size A- / A+ controls -- 15 tappable references to guidelines and trials -- Works fully offline REFERENCES INCLUDE: ICSD-3 (AASM 2014), AASM Clinical Practice Guidelines 2021, NICE NG218 RLS 2023, EAN Narcolepsy Guidelines 2022, IRLSSG Diagnostic Criteria 2014, NICE TA609 Pitolisant, NICE TA320 Sodium Oxybate, Postuma RBD Neurodegeneration 2019, Johns ESS 1991, BNF. For qualified healthcare professionals only. NOT a regulated medical device under MHRA Software Guidance 2020, EU MDR Article 2(1), and FDA 21st Century Cures Act Section 3060.